Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Skin sensitisation

Currently viewing:

Administrative data

Endpoint:
skin sensitisation: in vivo (LLNA)
Type of information:
experimental study
Adequacy of study:
key study
Study period:
08.12.2022-31.1.2023
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
2023
Report date:
2023

Materials and methods

Test guideline
Qualifier:
according to guideline
Guideline:
OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
Version / remarks:
2010
GLP compliance:
yes (incl. QA statement)
Type of study:
mouse local lymph node assay (LLNA)

Test material

1
Chemical structure
Reference substance name:
1-[4-(1,1-dimethylethyl)phenyl]-3-(4-methoxyphenyl)propane-1,3-dione
EC Number:
274-581-6
EC Name:
1-[4-(1,1-dimethylethyl)phenyl]-3-(4-methoxyphenyl)propane-1,3-dione
Cas Number:
70356-09-1
Molecular formula:
C20H22O3
IUPAC Name:
1-(4-tert-butylphenyl)-3-(4-methoxyphenyl)propane-1,3-dione
Test material form:
solid: particulate/powder
Details on test material:
- Name of test material: BMDBM, Butyl methoxydibenzoyl methane
- Substance type: mono constituent
- Appearance: Solid white to pale yellow powder
Specific details on test material used for the study:
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: at room temperature, protected from light

In vivo test system

Test animals

Species:
mouse
Strain:
CBA/Ca
Remarks:
CBA/CaOlaHsd mice
Sex:
female
Details on test animals and environmental conditions:
TEST ANIMALS
- Source: Envigo RMS B.V., Inc
- Microbiological status of animals, when known:
- Age at study initiation: 1st pre-test: 17 weeks; 2nd pre-test & main study: 8 - 12 weeks
- Weight at study initiation: 1st pre-test: 25 g (1 animal); 2nd pre-test: 17.1 g (1 animal) main study: 18.6 g average (16 animals)
- Housing: per group; Makrolon Type II (pre-test) / III (main study), with wire mesh top
- Diet: 2018C Teklad Global 18% protein rodent diet(certified), ad libitum
- Water: tap water, ad libitum
- Acclimation period: At least 5 days prior to the start of dosing
- Indication of any skin lesions:

ENVIRONMENTAL CONDITIONS
- Temperature: 22 ± 2°C
- Humidity: 45-65%
- Air changes (per hr): 15
- Photoperiod: artificial light 6.00 a.m. - 6.00 p.m.

Study design: in vivo (LLNA)

Vehicle:
dimethylformamide
Remarks:
The highest test item concentration, which could be technically used was a 50% solution in DMF. Vortexing was used to formulate the test item.
Concentration:
10%, 25%, 50%
No. of animals per dose:
4
Details on study design:
PRE-SCREEN TESTS:
To determine the highest non-irritant test concentration that at the same time did not induce signs of systemic toxicity, a pre-test was performed in one animal. One mouse was treated by (epidermal) topical application to the dorsal surface of each ear with a test item concentration of 50% once daily each on three consecutive days. Prior to the first application of the test item and before sacrifice the body weight was determined. Clinical signs were recorded at least once daily. Eventual signs of local irritation were documented and a score was used to grade a possible erythema of the ear skin. Furthermore, prior to the first application of the test item (day 1), on day 3 and before sacrifice (day 6) the ear thickness was determined using a micrometer. Additionally, the ears were punched after sacrifice (day 6) at the apical area using a biopsy punch (Ø 8 mm corresponding to 0.5 cm²) and were immediately pooled and weighed using an analytical balance. The animal showed an erythema of the ear skin (Score 1), and, after each application mild and unspecific signs of discomfort such as piloerection, partially closed eyes, decreased activity, and hunched posture. An erythema of ear skin could not always be determined due to substance residuals. Since a relatively high ear thickness value was determined on day 6, which was not accompanied by a similar increase in the other irritation parameters (i.e., ear weights, erythema score), a confirmatory second pre-test was performed in one further animal using a test item concentration of 50% again. The animal showed again mild and unspecific signs of discomfort such as decreased activity, hunched posture, nervousness, and partially closed eyes as well as slightly scaly ears. This time, however, all parameters for possible local skin irritation (ear weights, ear thickness, erythema score) were well within the Guideline-recommended thresholds. A possible erythema of ear skin could not always be determined due to test substance residuals.
Thus, the test item in the main study was assayed at 10, 25, and 50%. The highest concentration tested was the highest level that could be achieved whilst avoiding systemic toxicity and excessive local skin irritation as confirmed in the pre-experiment.

- Ear Thickness: In the pre-test, the ear thickness was determined prior to the first application of the test item (day 1), on day 3, and on day 6 prior to sacrifice using a micrometer.
- Ear Weights: In the pre-test, after the lymph nodes have been excised, both ears of mice were punched at the apical area using a biopsy punch (Ø 8 mm corresponding to 0.5 cm²). For each animal both

MAIN STUDY
Each test group of mice was treated by (epidermal) topical application to the dorsal surface of each ear with test item concentrations of 10, 25, and 50% in DMF. The application volume, 25 µL/ear/day, was spread over the entire dorsal surface (Ø 8 mm) of each ear once daily for three consecutive days. A further group of mice (control animals) was treated with an equivalent volume of the relevant vehicle alone (control animals).

Five days after the first topical application (day 6) 250 µL of phosphate-buffered saline containing 20.4 µCi of 3H-methyl thymidine (equivalent to 81.4 µCi/mL 3HTdR) were injected into each test and control mouse via the tail vein.

Approximately five hours after treatment with 3HTdR all mice were euthanized by using CO2, which was, after harvesting of the lymph nodes, followed by cervical dislocation to ensure death.

The draining lymph nodes were rapidly excised and pooled for each experimental group (8 nodes per group). Single cell suspensions (in phosphate buffered saline) of pooled lymph node cells were prepared by gentle mechanical disaggregation through stainless steel gauze (200 µm mesh size). After washing two times with phosphate buffered saline (approx. 10 mL) the lymph node cells were resuspended in 5 % trichloroacetic acid (approx. 3 mL) and incubated at approximately +4 °C for at least 18 hours for precipitation of macromolecules.

The precipitates were then resuspended in 5 % trichloroacetic acid (1 mL) and transferred to scintillation vials with 10 mL of scintillation liquid and thoroughly mixed. The level of 3HTdR incorporation was then measured in a β-scintillation counter. Similarly, background 3HTdR levels were also measured in two 1 mL aliquots of 5 % trichloroacetic acid. The -scintillation counter expresses 3HTdR incorporation as the number of radioactive disintegrations per minute (DPM).

- Clinical observation: All animals were observed on a daily basis, including pre- and post-dose observations on days 1, 2 and 3. Any clinical signs of systemic toxicity, local skin irritation or signs of ill health during the study were recorded.
punches were immediately weighed per animal using an analytical balance.
- Body weights: The body weights were recorded on day 1 (prior to dosing) and prior to sacrifice (pre-test) or prior to treatment with 3HTdR (main experiment)
Positive control substance(s):
other:
Statistics:
The mean values and standard deviations were calculated in the body weight tables.

Results and discussion

In vivo (LLNA)

Resultsopen allclose all
Parameter:
SI
Value:
1
Test group / Remarks:
control
Parameter:
SI
Value:
1.17
Test group / Remarks:
10%
Parameter:
SI
Value:
1.48
Test group / Remarks:
25%
Parameter:
SI
Value:
1.8
Test group / Remarks:
50%
Cellular proliferation data / Observations:
EC3 CALCULATION
The EC3 value could not be calculated, since all S.I.´s are below the threshold value of 3.

CLINICAL OBSERVATIONS:
No signs of systemic toxicity were observed during the study period.
The animals treated with test item concentrations of 25 and 50% showed a very slight erythema of the ear skin (Score 1) on test day 3 only. Animals treated with 10% test item concentration did not show any signs of local skin irritation. An erythema of ear skin could not always be determined due to substance residuals.

BODY WEIGHTS
The body weight of the animals, recorded prior to the first application and prior to treatment with 3HTdR, was within the range commonly recorded for animals of this strain and age.

Any other information on results incl. tables








































































Test item concentration %



Group



Measurement DPM



Calculation



Result



DPM-BGa)



number of lymph nodes



DPM per lymph nodeb)



S.I.



---



BG I



23



---



---



---



---



---



BG II



21



---



---



---



---



0



1



7722



7700



8



962.5



1.00



10



2



9042



9020



8



1127.5



1.17



25



3



11387



11365



8



1420.6



1.48



50



4



13903



13881



8



1735.1



1.80



1 = Control Group


2-4 = Test Group


a) = The mean value was taken from the figures BG I and BG II


b) =Since the lymph nodes of the animals of a dose group were pooled, DPM/node was determined by dividing the measured value by the number of lymph nodes pooled


 


 

Applicant's summary and conclusion

Interpretation of results:
GHS criteria not met
Conclusions:
The test item was not a skin sensitiser under the test conditions of this study.
Executive summary:

In this study the test item formulated in dimethylformamide (DMF) was assessed for its possible skin sensitising potential. For this purpose a local lymph node assay was performed using test item concentrations of 10, 25, and 50% (w/w). The highest concentration tested was the highest concentration that could be achieved whilst avoiding systemic toxicity and excessive local skin irritation as confirmed by two pre-experiments. The animals did not show any signs of systemic toxicity during the course of the study and no cases of mortality were observed. The animals treated with a test item concentration of 25 and 50% showed a very slight erythema of the ear skin (Score 1) on test day 3 only. Animals treated with 10% test item concentration did not show any signs of local skin irritation. In this study Stimulation Indices (S.I.) of 1.2, 1.5, and 1.8 were determined with the test item at concentrations of 10, 25, and 50% in DMF, respectively. The test item was not a skin sensitiser under the test conditions of this study.